Literature DB >> 30428389

Prognostic significance of Ki-67 levels and hormone receptor expression in low-grade serous ovarian carcinoma: an investigation of the Tumor Bank Ovarian Cancer Network.

Jalid Sehouli1, Elena Ioana Braicu2, Rolf Richter2, Carsten Denkert3, Paul Jank3, Philipp Sebastian Jurmeister3, Catarina Alisa Kunze3, Jan Budczies3, Sylvia Darb-Esfahani4, Wolfgang Daniel Schmitt3, Alexander Traut5, Jacek Grabowski6, Eliane Tabea Taube3, Helmut Plett7.   

Abstract

Low-grade serous ovarian carcinoma (LGSOC) has recently come up as a distinct rare entity of epithelial ovarian cancer. Predictive and prognostic markers are not well studied yet. Because Ki-67 and hormone receptors (HR) have been established as relevant cancer biomarkers in several malignant tumors, we evaluated Ki-67 and HR expression rates by immunohistochemistry in 68 patients with LGSOC. We used a standardized cutoff finder algorithm to analyze prognostic significance for overall survival (OS) and progression-free survival (PFS). Cox regression showed a significant continuous decrease in OS for higher proliferation rates with an HR  of 1.07% (95% confidence interval, 1.01%-3.67%; P = .048) but not in PFS (P = .86). Cutoff finder analysis revealed the best possible cutoff for OS at 6.28% (P = .04) and for PFS at 1.85% proliferative activity (P = .04). Estrogen receptors (ERs) were expressed in most LGSOC patients (n = 61; 89.7%), progesterone receptor (PR) in about half of patients (n = 33; 48.5%). For both ER/PR, a statistically significant cutoff for PFS could be determined, which was at 75% of positive tumor cells for ER (P = .02) and at 15% of positive tumor cells for PR (P = .03). For OS, HR expression showed a tendency toward better OS for HR-positive tumors but did not turn out statistically significant. Our results show that Ki-67 is a valuable prognostic marker in the subgroup of LGSOC. We could also show that most LGSOCs express HRs but that this expression is associated with a better PFS, a finding valuable in times of antihormonal therapy in LGSOC.
Copyright © 2018. Published by Elsevier Inc.

Entities:  

Keywords:  Hormone receptor; Ki-67; Low-grade serous ovarian carcinoma; Prognostic marker; Proliferative activity

Mesh:

Substances:

Year:  2018        PMID: 30428389     DOI: 10.1016/j.humpath.2018.10.020

Source DB:  PubMed          Journal:  Hum Pathol        ISSN: 0046-8177            Impact factor:   3.466


  3 in total

1.  Molecular characterization of low-grade serous ovarian carcinoma identifies genomic aberrations according to hormone receptor expression.

Authors:  Dane Cheasley; Marta Llaurado Fernandez; Martin Köbel; Hannah Kim; Amy Dawson; Joshua Hoenisch; Madison Bittner; Derek S Chiu; Aline Talhouk; C Blake Gilks; Madawa W Jayawardana; Kathleen I Pishas; Anne-Marie Mes-Masson; Diane Provencher; Abhimanyu Nigam; Neville F Hacker; Kylie L Gorringe; Ian G Campbell; Mark S Carey
Journal:  NPJ Precis Oncol       Date:  2022-06-29

Review 2.  Low-Grade Serous Carcinoma of the Ovary: The Current Status.

Authors:  Abdulaziz Babaier; Hanan Mal; Waleed Alselwi; Prafull Ghatage
Journal:  Diagnostics (Basel)       Date:  2022-02-10

3.  Advanced low grade serous ovarian cancer: A retrospective analysis of surgical and chemotherapeutic management in two high volume oncological centers.

Authors:  Paolo Di Lorenzo; Vincenza Conteduca; Emanuela Scarpi; Marco Adorni; Francesco Multinu; Annalisa Garbi; Ilaria Betella; Tommaso Grassi; Tommaso Bianchi; Giampaolo Di Martino; Andrea Amadori; Paolo Maniglio; Isabella Strada; Silvestro Carinelli; Marta Jaconi; Giovanni Aletti; Vanna Zanagnolo; Angelo Maggioni; Luca Savelli; Ugo De Giorgi; Fabio Landoni; Nicoletta Colombo; Robert Fruscio
Journal:  Front Oncol       Date:  2022-09-27       Impact factor: 5.738

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.